Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2/3 extension study of subcutaneous sibeprenlimab in IgA nephropathy
MOH_2025-03-09_013965Phase 3Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sibeprenlimab in IgA nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Co., Ltd. Started Feb 2025; status: active, not recruiting.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2025-03-09_013965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-09_013965.